Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease

This study is testing whether combining near-infrared light therapy (a type of gentle light treatment applied to the head) with the Alzheimer's drug lecanemab can slow cognitive decline in people with mild Alzheimer's disease. **You may be eligible if...** - You are aged 50–90 years - You have been diagnosed with probable Alzheimer's disease - An amyloid PET scan has confirmed abnormal amyloid deposits in your brain - Your cognitive impairment is mild (CDR global score of 1, MMSE score of 15 or higher) - You have a caregiver who can help you with daily device use and assessments **You may NOT be eligible if...** - Your memory problems are caused by something other than Alzheimer's (e.g., vascular dementia only, psychiatric illness) - You carry two copies of the APOE ε4 gene - You have more than 5 tiny bleeds in the brain on MRI - You are on blood thinners - You have had epilepsy or a bleeding stroke in the past year - You have an allergy to light or implanted metal devices in your head Talk to your doctor to see if this trial is right for you.